FDAnews Drug Daily Bulletin

NEUROGESX RAISES $20 MILLION IN PRIVATE EQUITY FINANCING; PROCEEDS TO FUND U.S. PIVOTAL CLINICAL TRIALS

Dec. 2, 2005
A A

NeurogesX, Inc., a privately held specialty pharmaceutical company focused on the development and commercialization of novel treatments for relief of neuropathic pain, today announced that it has completed a $20 million private equity financing. The company believes that proceeds from this financing will be sufficient to complete its current U.S. pivotal clinical program and to support its European marketing application for Transacin(TM), NeurogesX's proprietary dermal patch for the treatment of neuropathic pain.

Business Wire (http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20051201005254&newsLang=en)